Plus Therapeutics
OverviewSuggest Edit
Plus Therapeutics (formerly known as Cytori Therapeutics) is a pharmaceutical company focused on the discovery, development, and manufacturing of treatments for patients battling cancer and other life-threatening diseases. The company delivers a range of drugs using liposomal encapsulation technology.
| Type | Public | |
| Founded | 1996 | |
| HQ | Austin, TX, US | Map |
| Website | plustherapeutics.com | |
| Employee Ratings | More |
Recent NewsAll News
- Thinking about buying stock in Plus Therapeutics, AMC Entertainment, ProQR Therapeutics, Nokia, or Diana Shipping?
- Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements
- Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
- Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization
Key People/Management at Plus Therapeutics
Marc Hedrick
President and CEO
Andrew Sims
Vice President and Chief Financial Officer
Cheri Rice
Vice President - Product Development
Russ Havranek
Vice President - Corporate Strategy and New Product Planning
Richard Hawkins
Chairman
Greg Petersen
Director
Plus Therapeutics Office Locations
Plus Therapeutics has offices in Austin and San Antonio
Austin, TX, US (HQ)
4200 Marathon Blvd #200
San Antonio, TX, US
12500 Network Blvd
Plus Therapeutics Financials and Metrics
Plus Therapeutics Revenue
Plus Therapeutics's revenue was reported to be $7 m in FY, 2019 which is a 90.6% increase from the previous period.
| USD | |
|---|---|
Net income (Q1, 2021) | (2.7m) |
EBIT (Q1, 2021) | (2.5m) |
Market capitalization (4-Jun-2021) | 57.4m |
Closing stock price (4-Jun-2021) | 2.7 |
Cash (31-Mar-2021) | 14.4m |
EV | 49.5m |
Plus Therapeutics's current market capitalization is $57.4 m.
Annual
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 5.9m | 3.1m | 6.8m | 3.9m | 4.5m | 16.8m | 16.1m | 9.3m | 7.6m | 14.4m |
Accounts Receivable | 769.0k | 399.0k | 440.0k | 455.0k | 80.0k | 4.8m | 978.0k | 951.0k | ||
Inventories | 3.2m | 3.0m | 2.8m | 3.0m | 107.0k | 107.0k | 107.0k | 107.0k | 107.0k | |
Current Assets | 10.7m | 7.4m | 10.8m | 8.5m | 5.3m | 22.3m | 17.7m | 10.8m | 8.6m | 15.4m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.4m) | (8.1m) | (10.4m) | (3.1m) | (12.3m) | (11.8m) | (1.1m) | (2.9m) | (4.7m) | (2.7m) |
Depreciation and Amortization | 497.0k | 975.0k | 1.5m | 443.0k | 617.0k | 778.0k | 94.0k | 188.0k | 273.0k | 88.0k |
Inventories | 141.0k | 371.0k | 615.0k | 16.0k | 235.0k | 274.0k | ||||
Accounts Payable | (556.0k) | (1.2m) | (1.3m) | (405.0k) | (94.0k) | (95.0k) | 410.0k | 371.0k | (1.6m) | (461.0k) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 173.3k |
Debt/Equity | 1 x |
Debt/Assets | 0.4 x |
Financial Leverage | 2.4 x |
Plus Therapeutics Cybersecurity Score
Plus Therapeutics Online and Social Media Presence
189 Twitter followers
Plus Therapeutics has 189 Twitter Followers. The number of followers has increased 8.2% month over month and increased 56.3% quarter over quarter
Plus Therapeutics's Trends
Twitter Engagement Stats for @plustxinc
112
Tweets
630
Following
189
Followers
3
Tweets last 30 days
1.3
Avg. likes per Tweet
66.7%
Tweets with engagement
Plus Therapeutics News and Updates
May 04, 2021
Thinking about buying stock in Plus Therapeutics, AMC Entertainment, ProQR Therapeutics, Nokia, or Diana Shipping?
NEW YORK, May 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PSTV, AMC, PRQR, NOK, and DSX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 04, 2021
Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements
– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply
April 08, 2021
Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021
AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter 2021…
March 23, 2021
Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization
Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets
March 03, 2021
Plus Therapeutics to Participate in Upcoming Virtual Conferences
AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Off…
February 22, 2021
Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –
Plus Therapeutics Frequently Asked Questions
When was Plus Therapeutics founded?
Plus Therapeutics was founded in 1996.
Who are Plus Therapeutics key executives?
Plus Therapeutics's key executives are Marc Hedrick, Andrew Sims and Cheri Rice.
How many employees does Plus Therapeutics have?
Plus Therapeutics has 12 employees.
Who are Plus Therapeutics competitors?
Competitors of Plus Therapeutics include Praedicare Labs, Allogene Therapeutics and AVEO Pharmaceuticals.
Where is Plus Therapeutics headquarters?
Plus Therapeutics headquarters is located at 4200 Marathon Blvd #200, Austin.
Where are Plus Therapeutics offices?
Plus Therapeutics has offices in Austin and San Antonio.
How many offices does Plus Therapeutics have?
Plus Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies